APOE and Alzheimer disease: We explored data from ADNI, NACC, and ROS/MAP/MARS to estimate the 5-year risk of a first diagnosis of MCI or dementia due to AD for the target population of 60- to 75-year-old APOE4 homozygotes of Generation Study 1.